NS3623 is a novel human RBC Cl-conductance blocker (IC50=210 nM) and HERG channel activitor (EC50=79.4 uM, HERG1 channel activation).
NS-3623 inhibits RBC g(Cl) after oral administration to normal mice (ED50= 25 mg/kg), ameliorates erythrocyte dehydration in transgenic SAD mice.
NS-3623 increases the macroscopic current conducted by the hERG channels by increasing the time constant for channel inactivation.
NS-3623 affects native I(Kr), decreases QT variability and distinctly decreases the occurrence of extrasystoles in the acutely bradypaced hearts.
